Clinical Trial Finder
Anti-Infective Closed to Enrollment
STOP 2: Treatment of pulmonary exacerbations in people with CF (STOP2-IP-15)
This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of different lengths of IV treatment for pulmonary exacerbations in people with CF.
Pulmonary exacerbations are treated with varying antibiotics for varying time periods based on individual needs determined by patients, their families and care providers. This study will look at the safety and effectiveness of three different lengths of IV antibiotic treatment for pulmonary exacerbations. Participants who respond early to IV treatment will receive antibiotics for 10 or 14 days. Those who do not respond early will receive antibiotics for 14 or 21 days. Researchers will study the effectiveness of different IV treatment lengths by measuring changes in lung function.This study is for people with CF who experience a pulmonary exacerbation and are planning to receive IV antibiotic treatment. This study may require lung function tests and/or other measurements.
Eligibility
-
Age:
18 Years and Older -
Mutation(s):
No Mutation Requirement -
FEV1% Predicted:
No FEV1 Limit
For more information about the results of this study and where it was conducted, visit ClinicalTrials.gov.
Study Design
-
Study Type: ?more info
Interventional -
Randomized Study: ?more info
Yes -
Placebo Controlled: ?more info
No -
Length of Participation:
35 days -
Number of Study Visits:
3
Additional Information
-
Phase: ?more info
Not Applicable -
Study Sponsor: ?more info
Flume, Patrick -
Study Drugs:
N/A
Study Sites
-
Closed to Enrollment
Alabama
University of Alabama at Birmingham, Birmingham, AL 35294
-
Closed to Enrollment
Alaska
Providence Alaska Medical Center, Anchorage, AK 99508
-
Closed to Enrollment
Arizona
Tucson Cystic Fibrosis Center, Tucson, AZ 85724
-
Closed to Enrollment
California
University of California at Davis Medical Center, Sacramento, CA 95817
-
Closed to Enrollment
California
University of California San Diego, La Jolla, CA 92093
-
Closed to Enrollment
California
Stanford University Medical Center, Palo Alto, CA 94304
-
Closed to Enrollment
Colorado
National Jewish Health, Denver, CO 80206
-
Closed to Enrollment
Connecticut
Yale University School of Medicine, New Haven, CT 06520
-
Closed to Enrollment
Connecticut
The Marie and Raymond Beauregard Adult CF Center at Hartford Hospital, Hartford, CT 06102
-
Closed to Enrollment
Florida
University of Florida, Gainesville, FL 32610
-
Closed to Enrollment
Florida
University of Miami, Miami, FL 33136
-
Closed to Enrollment
Florida
Joe DiMaggio Children's Hospital, Hollywood, FL 33021
-
Closed to Enrollment
Georgia
Augusta University, Augusta, GA 30912
-
Closed to Enrollment
Georgia
Emory University, Atlanta, GA 30327
-
Closed to Enrollment
Idaho
Saint Luke's Cystic Fibrosis Center of Idaho, Boise, ID 83702
-
Closed to Enrollment
Illinois
OSF Saint Francis Medical Center, Peoria, IL 61637
-
Closed to Enrollment
Indiana
Indiana University Medical Center, Indianapolis, IN 46202
-
Closed to Enrollment
Kansas
University of Kansas Medical Center, Kansas City, KS 66160
-
Closed to Enrollment
Maryland
Johns Hopkins University, Baltimore, MD 21205
-
Closed to Enrollment
Massachusetts
University of Massachusetts Memorial Health Care, Worcester, MA 01605
-
Closed to Enrollment
Massachusetts
Boston Children's Hospital, Brigham & Women's Hospital, Boston, MA 02115
-
Closed to Enrollment
Michigan
University of Michigan Health System, Ann Arbor, MI 48109
-
Closed to Enrollment
Michigan
Wayne State University Harper University Hospital, Detroit, MI 48201
-
Closed to Enrollment
Missouri
Washington University School of Medicine, St. Louis, MO 63110
-
Closed to Enrollment
Missouri
SSM Health Saint Louis University Hospital, St. Louis, MO 63110
-
Closed to Enrollment
Montana
Billings Clinic , Billings, MT 59101
-
Closed to Enrollment
New Hampshire
Dartmouth Hitchcock Medical Center, Lebanon, NH 03756
-
Closed to Enrollment
New Jersey
Morristown Medical Center , Morristown, NJ 07960
-
Closed to Enrollment
New Jersey
Monmouth Medical Center, Eatontown, NJ 07724
-
Closed to Enrollment
New Jersey
Rutgers - Robert Wood Johnson Medical School, New Brunswick, NJ 08903
-
Closed to Enrollment
New York
Long Island Jewish Medical Center, New Hyde Park, NY 11042
-
Closed to Enrollment
New York
Columbia University Cystic Fibrosis Program, New York, NY 10032
-
Closed to Enrollment
New York
Beth Israel Medical Center, New York, NY 10003
-
Closed to Enrollment
New York
SUNY Upstate Medical University, Syracuse, NY 13210
-
Closed to Enrollment
New York
New York Medical College at Westchester Medical Center, Valhalla, NY 10595
-
Closed to Enrollment
New York
The Cystic Fibrosis Center of Western New York, Buffalo, NY 14203
-
Closed to Enrollment
New York
University of Rochester Medical Center Strong Memorial, Rochester, NY 14609
-
Closed to Enrollment
North Carolina
University of North Carolina at Chapel Hill, Chapel Hill, NC 27517
-
Closed to Enrollment
North Carolina
Wake Forest University Baptist Medical Center, Winston-Salem, NC 27157
-
Closed to Enrollment
Ohio
Nationwide Children's Hospital, Columbus, OH 43205
-
Closed to Enrollment
Ohio
Dayton Adult CF Program, Dayton, OH 45404
-
Closed to Enrollment
Ohio
Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center, Cleveland, OH 44146
-
Closed to Enrollment
Ohio
Children's Hospital Medical Center of Akron, Akron, OH 44308
-
Closed to Enrollment
Pennsylvania
Hershey Medical Center Pennsylvania State University, Hershey, PA 17033
-
Closed to Enrollment
Pennsylvania
University of Pennsylvania, Philadelphia, PA 19104
-
Closed to Enrollment
Pennsylvania
University of Pittsburgh Medical Center, Pittsburgh, PA 15224
-
Closed to Enrollment
South Carolina
Medical University of South Carolina, Charleston, SC 29425
-
Closed to Enrollment
Texas
Baylor College of Medicine, Houston, TX 77030
-
Closed to Enrollment
Texas
University of Texas Southwestern, Dallas, TX 75390
-
Closed to Enrollment
Texas
University of Texas Health Center at Tyler, Tyler, TX 75708
-
Closed to Enrollment
Vermont
University of Vermont Medical Center, Burlington, VT 05401
-
Closed to Enrollment
Virginia
Virginia Commonwealth University, Richmond, VA 23298
-
Closed to Enrollment
Virginia
University of Virginia, Charlottesville, VA 22908
-
Closed to Enrollment
Washington
University of Washington Medical Center, Seattle, WA 98195
-
Closed to Enrollment
West Virginia
West Virginia University - Morgantown, Morgantown, WV 26507
-
Closed to Enrollment
Wisconsin
University of Wisconsin, Madison, WI 53792
-
Closed to Enrollment
Wisconsin
Froedtert & Medical College of Wisconsin, Milwaukee, WI 53226
Eligibility
-
Age:
18 Years and Older -
Mutation(s):
No Mutation Requirement -
FEV1% Predicted:
No FEV1 Limit
For more information about the results of this study and where it was conducted, visit ClinicalTrials.gov.
Related Topics
-
Questions to Ask When Considering a Specific Trial
Clinical trials that test potential drugs and therapies in people with cystic fibrosis are a major part of CF research. They take place at Cystic Fibrosis Foundation-accredited care centers all over the United States and enroll people with CF of all ages.
-
Patient Safety Is a Priority
Nothing is more important than patient safety in developing new treatments for cystic fibrosis. The U.S. government requires that all clinical trials are supervised for safety, and the Cystic Fibrosis Foundation adds additional measures to protect study volunteers.
-
Trikafta™
The following is a collection of information and news about Trikafta™, the triple-combination modulator therapy that was approved by the U.S. Food and Drug Administration on Oct. 21, 2019.
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More